Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVJB09)

• Drug Name: MK-1903 Drug Info
• Synonyms: Second-generation niacin receptor agonists (oral, atherosclerosis), Arena/Merck & Co

Indication

Disease Entry	ICD 11	Status	REF
Arteriosclerosis	BD40	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 49763030
  CAS Number: CAS 1268882-43-4
  TTD Drug ID: DMVJB09

Molecule-Related Drug Atlas

Drug(s) Targeting Nicotinic acid receptor (HCAR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Vitamin B3	DMQVRZH	Chronic renal failure	GB61.Z	Approved	[3]
ARI-3037MO	DM9LNXS	Cardiovascular disease	BA00-BE2Z	Phase 2	[4]
SCH-900271	DMBJY1Z	Ischemic stroke	8B11.5Z	Phase 2	[5]
GSK-256073	DMMAIY2	Hyperlipidaemia	5C80	Phase 2	[6]
MK-0354	DMWFTRJ	N. A.	N. A.	Phase 2	[7]
NIA-114	DM3ADQW	Plaque psoriasis	EA90.0	Clinical trial	[8]
INCB19602	DMRHZBD	Type-2 diabetes	5A11	Discontinued in Phase 2	[9]
cinnamic acid	DM340FH	Discovery agent	N.A.	Investigative	[10]
5-Benzyl-1H-pyrazole-3-carboxylic acid	DMJVGUZ	Discovery agent	N.A.	Investigative	[11]
Sazetidine-A	DM68JI5	Major depressive disorder	6A70.3	Investigative	[5]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Nicotinic acid receptor (HCAR2)	TTWNV8U	HCAR2_HUMAN	Agonist	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5785).
• [2] Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci Transl Med. 2012 Aug 22;4(148):148ra115.
• [3] Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, Greatens A, Hillebrand GG, Bissett DL, Boissy RE: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002 Jul;147(1):20-31.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Discovery of SCH 900271, a Potent Nicotinic Acid Receptor Agonist for the Treatment of Dyslipidemia. ACS Med Chem Lett. 2011 Nov 24;3(1):63-8.
• [6] GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2013 Nov;15(11):1013-21.
• [7] GPR109a agonists. Part 2: pyrazole-acids as agonists of the human orphan G-protein coupled receptor GPR109a. Bioorg Med Chem Lett. 2010 Aug 1;20(15):4472-4.
• [8] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [9] DOI: 10.1038/scibx.2010.313
• [10] Phenolic acids suppress adipocyte lipolysis via activation of the nicotinic acid receptor GPR109A (HM74a/PUMA-G). J Lipid Res. 2009 May;50(5):908-14.
• [11] Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J Med Chem. 2003 Aug 28;46(18):3945-51.